Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481130 · ClinicalTrials.gov registry record
Alport Syndrome Treatments and Outcomes Registry
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 655
- Enrollment target
NCT00481130: Completed study, sponsored by University of Minnesota.
NCT00481130 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 655 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00481130 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 655 participants
- Enrollment target
Study Summary
ASTOR's primary purpose is to enroll families and patients with a history of Alport syndrome in a central registry. The information we gather will be used as a basis for studies designed to test potential treatments for Alport syndrome. ASTOR also aims to provide patients, families and physicians with the most up-to-date information about Alport syndrome.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 655 participants |
| Start Date | 2007-09 |
| Est. Completion | 2025-11-17 |
What the finished NCT00481130 record still lists
NCT00481130 is an observational study that tracks outcomes without assigning an intervention. The registered 655 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00481130 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00481130 about?
NCT00481130 is a clinical study titled "Alport Syndrome Treatments and Outcomes Registry". ASTOR's primary purpose is to enroll families and patients with a history of Alport syndrome in a central registry. The information we gather will be used as a basis for studies designed to test potential treatments for Alport syndrome. ASTOR also aims to provide patients, families and physicians wi...
What is the current status of trial NCT00481130?
This trial is currently completed. The enrollment target is 655 participants. The study started on 2007-09. Estimated completion is 2025-11-17.
Who is sponsoring clinical trial NCT00481130?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07145515 · 655 participants · NA
Enhancing Heart Allograft Function With the OCS Heart System Trial
- NCT05407129 · 656 participants · NA
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
- NCT06127199 · 656 participants · NA
Contraceptive Efficacy Study of Ovaprene
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia